Meadowbrook Wealth Management LLC Grows Stake in AbbVie Inc. $ABBV

Meadowbrook Wealth Management LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 30.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,639 shares of the company’s stock after buying an additional 5,050 shares during the period. AbbVie makes up about 5.6% of Meadowbrook Wealth Management LLC’s investment portfolio, making the stock its 4th largest holding. Meadowbrook Wealth Management LLC’s holdings in AbbVie were worth $4,944,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ABBV. Vanguard Group Inc. boosted its position in AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after acquiring an additional 448,554 shares during the period. Norges Bank bought a new position in shares of AbbVie in the second quarter worth $4,288,200,000. Legal & General Group Plc increased its holdings in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP increased its holdings in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Finally, Amundi raised its stake in shares of AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company’s stock.

AbbVie Stock Performance

NYSE ABBV opened at $204.86 on Wednesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The business’s fifty day moving average is $222.48 and its two-hundred day moving average is $224.74. The stock has a market capitalization of $362.23 billion, a P/E ratio of 86.81, a P/E/G ratio of 0.71 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Citigroup dropped their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Finally, Guggenheim reiterated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑1 obesity data for ABBV‑295: AbbVie reported dose‑dependent, meaningful weight loss from ABBV‑295 (a long‑acting amylin analog), marking the company’s formal entry into the anti‑obesity market and diversifying revenue beyond immunology and oncology — a potentially material long‑term growth driver if later‑stage trials succeed. AbbVie’s ABBV-295 Obesity Data Opens New Non Incretin Opportunity
• Positive Sentiment: Multi‑year MLB partnership expands “Striking Out Cancer” nationally: AbbVie was named the Official Pharmaceutical Partner of Major League Baseball, amplifying its cancer‑support initiative, broadening brand reach and CSR impact (each MLB strikeout triggers donations to Stand Up To Cancer). This raises AbbVie’s consumer visibility and may help patient‑facing positioning. AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire) MLB: AbbVie named official pharmaceutical partner
• Positive Sentiment: Recent fundamentals and legal risk reduction support the story: AbbVie beat top‑line estimates in its latest quarter, raised FY‑2026 guidance, and a Bloomberg Law report shows the company prevailed in a worker’s suit over family‑medical‑history queries — reducing a potential legal overhang. These items support earnings visibility and dividend stability. AbbVie to sponsor leading US baseball league AbbVie beats worker’s suit (Bloomberg Law)
• Neutral Sentiment: Positive media/analyst commentary on valuation: Several outlets (The Motley Fool, Kalkine) highlight AbbVie’s dividend, revenue growth and argue the stock looks attractively valued, which may support longer‑term investor interest but is not an immediate catalyst. Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now AbbVie Shares Rise on Revenue Growth (Kalkine)
• Negative Sentiment: Valuation and technical/financial quirks may limit near‑term upside: AbbVie trades below its 50‑ and 200‑day moving averages and shows a high reported P/E (~86.8) and a negative ROE figure (accounting effect), factors that can pressure sentiment and constrain multiple expansion until growth visibility improves. MarketBeat ABBV snapshot

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.